Clinical trial · no report yet · Phase 1
ParadigMM-1B
A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
- NCT03287908 ↗
- Terminated
- Amgen
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1/2 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 701 Monotherapy, or in Combination With Pomalidomide, With and Without Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (ParadigMM-1B)
- Phase
- Phase 1
- Status
- Terminated
- Conditions
- Relapsed/Refractory Multiple Myeloma
- Interventions
- AMG 701; Pomalidomide; Dexamethasone
- Arms
- AMG 701 · Experimental
- AMG 701 + Pomalidomide · Experimental
- AMG 701 + Pomalidomide + Dexamethasone · Experimental
- Enrollment
- 174
- Primary outcomes
- Number of subjects with dose-limiting toxicities (DLTs)
- Number of subjects with treatment emergent adverse events (TEAEs)
- Number of subjects with treatment-related adverse events
- Number of subjects with disease-related adverse events
- Number of subjects with clinically-significant changes in vital signs
- Number of subjects with clinically-significant changes in physical examination measurements
- Number of subjects with clinically-significant changes in electrocardiogram (ECG) measurements
- Number of subjects with clinically-significant changes in clinical laboratory tests
- Sponsor
- Amgen
- Start
- Nov 13, 2017
- Primary completion
- Jun 30, 2023
- Results posted
- No
- Registry record
- NCT03287908 · updated Oct 8, 2025
Publications
linked from the registry- Lee HC, Plattel WJ, Harrison SJ, Sborov DW, Lentzsch S, Spencer A, Niesvizky R, Trudel S, Mollee P, Vij R, Minnema MC, Rasche L, Upreti VV, Zhou D, Xia Q, Talpes M, Eggert T, Kapoor P, Ailawadhi S. A phase 1/1b study of the BCMA-targeting bispecific T-cell engager pavurutamab for relapsed/refractory multiple myeloma. Blood. 2026 Jul 9;148(2):199-212. doi: 10.1182/blood.2025032044. PubMed 41950113
- Cho SF, Lin L, Xing L, Li Y, Wen K, Yu T, Hsieh PA, Munshi N, Wahl J, Matthes K, Friedrich M, Arvedson T, Anderson KC, Tai YT. The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models. Blood Adv. 2020 Sep 8;4(17):4195-4207. doi: 10.1182/bloodadvances.2020002524. PubMed 32898244